• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ERT announces enhancements on AVERT

ERT announces enhancements on AVERT

June 20, 2013
CenterWatch Staff

ERT, a global solution provider for patient safety and efficacy endpoint data collection, has announced enhancements to AVERT, its electronic suicide risk assessment system. Having captured over 100,000 assessments to date, AVERT is a tool for biopharmaceutical developers who need to assess for suicide risk during clinical development programs.

After being used by over 32,000 clinical trial patients, AVERT is now available in both audio (phone) and visual (web/tablet) patient interfaces, offering greater flexibility to developers of new biopharmaceutical products.

“It is critical for us to understand the complete safety profile of new drugs in development, especially if during the course of a trial patients experience suicidal ideation and behaviors,” said Carl Gommoll, senior director of clinical development at Forest Research Institute. “By administering AVERT we feel we are taking the most comprehensive and effective approach to identify the emergence of suicidal ideation and behaviors in order to enhance patient safety, which is our highest priority.”

Biopharmaceutical developers face the risk of treatment-emergent suicidal ideation and behavior (SIB) occurrence among patients in clinical trials. As a result of this safety risk, in 2012 the  FDA issued a revised Draft Guidance for Prospective Assessment of SIB in psychiatric and non-psychiatric trials. The guidance requires researchers in high-potential SIB risk areas to develop and follow study protocols that proactively assess SIB risk and enable proper behavioral health treatment for at-risk patients.

AVERT presents electronic administration of scientifically proven suicide risk assessment questionnaires. Its current application is delivered through an electronic patient self-rated version of the Columbia Suicide Severity Rating Scale (eC-SSRS), which is cited in the FDA guidance as an acceptable instrument for assessing SIB. Using AVERT, clinical trial patients can respond to a brief, SIB-related interview during investigative site visits or from home. If AVERT identifies an at-risk patient, the investigative site is alerted immediately, enabling them to take appropriate action per the protocol.

 “We are pleased to offer an enhanced version of AVERT that can be administered in a mode most comfortable for the patient, making the assessment of SIB risk more efficient and reliable for biopharmaceutical developers,” said Jeffrey Litwin, M.D., chief executive officer of ERT.

Upcoming Events

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing